Display options
Cite
da Silva SD, Hier M, Mlynarek A, et al. Recurrent oral cancer: current and emerging therapeutic approaches. Front Pharmacol. 2012;3:149doi: 10.3389/fphar.2012.00149.
da Silva, S. D., Hier, M., Mlynarek, A., Kowalski, L. P., & Alaoui-Jamali, M. A. (2012). Recurrent oral cancer: current and emerging therapeutic approaches. Frontiers in pharmacology, 3149. https://doi.org/10.3389/fphar.2012.00149
da Silva, Sabrina Daniela, et al. "Recurrent oral cancer: current and emerging therapeutic approaches." Frontiers in pharmacology vol. 3 (2012): 149. doi: https://doi.org/10.3389/fphar.2012.00149
da Silva SD, Hier M, Mlynarek A, Kowalski LP, Alaoui-Jamali MA. Recurrent oral cancer: current and emerging therapeutic approaches. Front Pharmacol. 2012 Jul 30;3:149. doi: 10.3389/fphar.2012.00149. eCollection 2012. PMID: 23060791; PMCID: PMC3459356.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2012 Jul 30;3:149. doi: 10.3389/fphar.2012.00149. eCollection 2012.

Recurrent oral cancer: current and emerging therapeutic approaches.

Frontiers in pharmacology

Sabrina Daniela da Silva, Michael Hier, Alex Mlynarek, Luiz Paulo Kowalski, Moulay A Alaoui-Jamali

Affiliations

  1. Department of Otolaryngology-Head and Neck Surgery, Sir Mortimer B. Davis-Jewish General Hospital, McGill University Montreal, QC, Canada ; Department of Medicine, Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University Montreal, QC, Canada ; Department of Oncology, Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University Montreal, QC, Canada.

PMID: 23060791 PMCID: PMC3459356 DOI: 10.3389/fphar.2012.00149

Abstract

Oral cavity cancer (OCC) is associated with high incidence of loco-regional recurrences, which account for the majority of treatment failures post-surgery and radiotherapy. The time-course of relapse manifestation and metastasis are unpredictable. Relapsed OCC represents a major clinical challenge in part due to their aggressive and invasive behaviors. Chemotherapy remains the only option for advanced OCC whenever salvage surgery or re-irradiation is not feasible, but its efficacy is limited as a result of the drug resistance development. Alternatives to use of different permutations of standard cytotoxic drugs or combinations with modulators of drug resistance have led to incremental therapeutic benefits. The introduction of targeted agents and biologics against selective targets that drive cancer progression has opened-up optimism to achieve superior therapeutic activity and overcome drug resistance because, unlike the non-selective cytotoxic, the target can be monitored at molecular levels to identify patients who can benefit from the drug. This review discusses the multifactorial aspects of clinical drug resistance and emerging therapeutic approaches in recurrent OCC, emphasizing recent advances in targeted therapies, immunotherapy, and potential relevance of new concepts such as epithelial-mesenchymal transition and cancer stem cell hypothesis to drug resistance.

Keywords: drug resistance; novel therapeutics; oral cancer; recurrence

References

  1. Cochrane Database Syst Rev. 2011 Apr 13;(4):CD006386 - PubMed
  2. J Clin Oncol. 2010 Feb 20;28(6):1075-83 - PubMed
  3. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18708-13 - PubMed
  4. Oral Oncol. 2005 May;41(5):534-41 - PubMed
  5. Drugs. 2010 Feb 12;70(3):273-86 - PubMed
  6. Cancer Treat Rev. 2008 Nov;34(7):577-91 - PubMed
  7. Oncogene. 2005 Nov 14;24(50):7443-54 - PubMed
  8. Nat Rev Drug Discov. 2012 Apr 13;11(5):384-400 - PubMed
  9. Ann Oncol. 1999;10 Suppl 6:77-82 - PubMed
  10. Nat Clin Pract Oncol. 2004 Nov;1(1):39-43 - PubMed
  11. Cell. 2008 May 16;133(4):704-15 - PubMed
  12. J Oral Pathol Med. 2000 May;29(5):226-31 - PubMed
  13. Ann Oncol. 2008 Jan;19(1):142-9 - PubMed
  14. N Engl J Med. 2007 Oct 25;357(17):1695-704 - PubMed
  15. Nat Rev Cancer. 2005 Apr;5(4):275-84 - PubMed
  16. Int J Oral Sci. 2011 Oct;3(4):180-91 - PubMed
  17. PLoS One. 2012;7(3):e34045 - PubMed
  18. J Chin Med Assoc. 2006 Oct;69(10):478-83 - PubMed
  19. Cancer. 2003 Aug 1;98(3):508-15 - PubMed
  20. Am J Pathol. 2002 Mar;160(3):985-1000 - PubMed
  21. J Clin Invest. 2000 Apr;105(8):1045-7 - PubMed
  22. Clin Cancer Res. 2000 Feb;6(2):347-52 - PubMed
  23. Clin Cancer Res. 2012 Jul 15;18(14):3750-61 - PubMed
  24. Curr Drug Targets. 2012 Jun;13(6):802-10 - PubMed
  25. Biochem Pharmacol. 2000 Oct 15;60(8):1091-9 - PubMed
  26. Drug Resist Updat. 2004 Aug-Oct;7(4-5):245-55 - PubMed
  27. Cancer Cell. 2012 Jan 17;21(1):66-81 - PubMed
  28. Nat Rev Clin Oncol. 2012 Apr 24;9(7):378-90 - PubMed
  29. Expert Opin Med Diagn. 2010 Jan 1;4(1):53-65 - PubMed
  30. Cells Tissues Organs. 2005;179(1-2):11-23 - PubMed
  31. Clin Cancer Res. 1999 May;5(5):1007-14 - PubMed
  32. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 - PubMed
  33. Nat Rev Clin Oncol. 2012 Feb 21;9(3):135-43 - PubMed
  34. Cancer Res. 1996 Jun 1;56(11):2488-92 - PubMed
  35. Clin Cancer Res. 2010 May 15;16(10):2709-14 - PubMed
  36. J Clin Invest. 2009 Jun;119(6):1429-37 - PubMed
  37. Cancer Res. 1996 Dec 15;56(24):5600-4 - PubMed
  38. Cell. 2012 Feb 3;148(3):399-408 - PubMed
  39. Mol Aspects Med. 2010 Apr;31(2):135-44 - PubMed
  40. Curr Opin Genet Dev. 2010 Feb;20(1):87-90 - PubMed
  41. Curr Pharm Des. 2007;13(32):3279-87 - PubMed
  42. Nat Rev Cancer. 2002 Jun;2(6):442-54 - PubMed
  43. Curr Pharm Des. 2010;16(12):1410-6 - PubMed
  44. Clin Cancer Res. 2000 Dec;6(12):4697-704 - PubMed
  45. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  46. Anticancer Drugs. 2011 Aug;22(7):626-33 - PubMed
  47. J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54 - PubMed
  48. Oral Oncol. 1999 May;35(3):257-65 - PubMed
  49. Cancer Res. 2002 Dec 1;62(23):6938-43 - PubMed
  50. Head Neck. 2010 Aug;32(8):997-1002 - PubMed
  51. Curr Opin Oncol. 2010 May;22(3):200-5 - PubMed
  52. J Clin Invest. 2002 Apr;109(8):987-91 - PubMed
  53. Nat Rev Drug Discov. 2011 Aug 31;10(9):671-84 - PubMed
  54. J Craniomaxillofac Surg. 2006 Sep;34(6):344-50 - PubMed
  55. Curr Opin Investig Drugs. 2010 Jun;11(6):615-28 - PubMed
  56. Curr Pharm Biotechnol. 2012 Sep;13(11):2259-72 - PubMed
  57. Oral Oncol. 2009 Apr-May;45(4-5):454-60 - PubMed
  58. Cancer. 2010 Jun 15;116(12):2856-67 - PubMed
  59. Recent Pat Anticancer Drug Discov. 2011 May;6(2):246-57 - PubMed
  60. Curr Med Chem Anticancer Agents. 2003 Nov;3(6):421-9 - PubMed
  61. Nat Rev Drug Discov. 2007 Apr;6(4):273-86 - PubMed
  62. J Clin Invest. 2012 May;122(5):1832-48 - PubMed
  63. Cancer Discov. 2012 Mar;2(3):214-26 - PubMed
  64. Adv Exp Med Biol. 2011;720:105-18 - PubMed
  65. Science. 2004 Mar 5;303(5663):1483-7 - PubMed
  66. Methods Mol Biol. 2008;468:5-15 - PubMed
  67. Cancer. 1994 Jan 1;73(1):187-90 - PubMed
  68. Nat Rev Cancer. 2009 Apr;9(4):265-73 - PubMed
  69. Nat Rev Drug Discov. 2011 Nov 11;10(12):915-29 - PubMed
  70. Am J Pathol. 1998 Jul;153(1):295-303 - PubMed
  71. Drugs. 2000;59 Suppl 4:9-17; discussion 37-8 - PubMed
  72. Expert Opin Ther Targets. 2007 Jul;11(7):915-27 - PubMed
  73. Oncogene. 2010 Feb 4;29(5):625-34 - PubMed
  74. Otolaryngol Head Neck Surg. 2005 Jun;132(6):862-8 - PubMed
  75. Mol Cancer Ther. 2008 Dec;7(12):3670-84 - PubMed
  76. Cancer Res. 2000 Apr 1;60(7):1878-86 - PubMed
  77. N Engl J Med. 2011 Oct 13;365(15):1449-50; author reply 1450 - PubMed
  78. Lancet Oncol. 2012 Mar;13(3):239-46 - PubMed
  79. Eur J Cancer. 1998 Sep;34(10):1522-34 - PubMed

Publication Types